CrossRef enabled

PAC Archives

Archive →

Pure Appl. Chem., 2007, Vol. 79, No. 12, pp. 2243-2261

http://dx.doi.org/10.1351/pac200779122243

Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology*

Michael J. Hannon

School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

References

  • 1. (a). Z. Guo, P. J. Sadler. Angew. Chem., Int. Ed. 38, 1512 (1999); (http://dx.doi.org/10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y)
  • 1. (b). T. Storr, K. H. Thompson, C. Orvig. Chem. Soc. Rev. 35, 534 (2006). (http://dx.doi.org/10.1039/b514859f)
  • 2. B. Lippert (Ed.). Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, Weinheim (1999).
  • 3. J. Reedijk. Chem. Commun. 801 (1996). (http://dx.doi.org/10.1039/cc9960000801)
  • 4. Z. J. Guo, P. J. Sadler. Adv. Inorg. Chem. 49, 183 (2000).
  • 5. J. D. Roberts, J. Peroutka, N. Farrell. J. Inorg. Biochem. 77, 51 (1999). (http://dx.doi.org/10.1016/S0162-0134(99)00147-6)
  • 6. S. J. Lippard, J. M. Berg. Principles of Bioinorganic Chemistry, University Science Books, Mill Valley, CA (1994).
  • 7. P. J. Dyson, G. Sava. Dalton Trans. 1929 (2006). (http://dx.doi.org/10.1039/b601840h)
  • 8. B. Rosenberg. In Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug, B.Lippert (Ed.), Wiley-VCH, Weinheim (1999).
  • 9. P. M. Takahara, A. C.Rosenzweig,C. A.Frederick,S. J.Lippard. Nature 377, 649 (1995). (http://dx.doi.org/10.1038/377649a0)
  • 10. U. M. Ohndorf, M. A.Rould, Q.He, C. O.Pabo, S. J. Lippard. Nature 399, 708 (1999). (http://dx.doi.org/10.1038/21460)
  • 11. M. J. Hannon. Chem. Soc. Rev. 36, 280 (2007). (http://dx.doi.org/10.1039/b606046n)
  • 12. M. J. Cleare, J. D. Hoeschele. Bioinorg. Chem. 2, 187 (1973). (http://dx.doi.org/10.1016/S0006-3061(00)80249-5)
  • 13. (a). For details on Satraplatin development, see <http://www.gpc-biotech.com/en/anticancer_programs/satraplatin/index.html>: <http://investor.pharmion.com/phoenix.zhtml?c=142045&p=irol-newsArticle&ID=1010774&highlight>;
  • 13. (b). For details on Miriplatin development, see <http://www.ds-pharma.co.jp/english/news/pdf/ne20060724.pdf>;
  • 13. (c). For details on ProLindac development, see <http://www.accesspharma.com/pr/070416.PDF>;
  • 13. (d). For details on BP-C1 development, see <http://www.meabco.com/RD%20BP-C1%20BC.htm>;
  • 13. (e). For details on cisplatin Lipid Complex development, see <http://www.transaveinc.com/products.shtml>;
  • 13. (f). For details on Aroplatin development, see <http://www.antigenics.com/products/cancer/aroplatin/>;
  • 13. (g). For details on Picoplatin development, see <http://www.poniard.com/> or <http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=246847>, which provides outline information on Picoplatin Phase II and III trials;
  • 13. (h). For other recent reviews, see L. R. Kelland. Nat. Rev. Cancer 7, 573 (2007);
  • 13. (i). M. D. Hall, H. R. Mellor, R. Callaghan, T. W. Hambley. J. Med. Chem. 50, 3403 (2007). (http://dx.doi.org/10.1021/jm070280u)
  • 14. (a). P. Beale, I. Judson, A. O'Donnell. Br. J. Cancer 88, 1128 (2003); (http://dx.doi.org/10.1038/sj.bjc.6600854)
  • 14. (b). J. Holford, S. Y. Sharp, B. A. Murrer, M. Abrams, L. R. Kelland. Br. J. Cancer 77, 366 (1998).
  • 15. T. Dragovich, D. Mendelson, S. Kurtin, K. Richardson, D. Von Hoff, A. Hoos. Cancer Chemother. Pharmacol. 58, 759 (2006). (http://dx.doi.org/10.1007/s00280-006-0235-4)
  • 16. G. P. Stathopoulos, T. Boulikas, M. Vougiouka, G. Deliconstantinos, S. Rigatos, E. Darli, V.Viliotoy, J. G. Stathopoulos. Oncol. Rep. 13, 589 (2005).
  • 17. B. Rosenberg, L. Van Camp, E. B. Grimley, A. J. Thomson. J. Biol. Chem. 242, 1347 (1967).
  • 18. G. Natile, M. Coluccia. Coord. Chem. Rev. 216-217, 383 (2001). (http://dx.doi.org/10.1016/S0010-8545(01)00315-0)
  • 19. N. Farrell, T. T. B. Ha, J.-P. Souchard, F. L. Wimmer, S. Cros, N. P. Johnson. J. Med. Chem. 32, 2240 (1989). (http://dx.doi.org/10.1021/jm00130a002)
  • 20. E. I. Montero, S. Diaz, A. M. Gonzalez-Vadillo, J. M. Perez, C. Alonso, C. Navarro-Ranninger. J. Med. Chem. 42, 4264 (1999). (http://dx.doi.org/10.1021/jm991015e)
  • 21. M. Coluccia, A. Nassi, F. Loseto, A. Boccarelli, M. A. Mariggio, D. Giordano, F. P. Intini, P. A. Caputo, G. Natile. J. Med. Chem. 36, 510 (1993). (http://dx.doi.org/10.1021/jm00056a012)
  • 22. N. Farrell. Metal Ions Biol. Sys. 41, 252 (2004).
  • 23. M. B. Kloster, J. C. Hannis, D. C. Muddiman, N. Farrell. Biochemistry 38, 14731 (1999). (http://dx.doi.org/10.1021/bi991202e)
  • 24. D. Jodrell, T. Evans, W. Steward, D. Cameron, J. Prendiville, C. Aschele, C. Noberasco, M. Lind, J. Carmichael, N. Dobbs. Eur. J. Cancer 40, 1872 (2004). (http://dx.doi.org/10.1016/j.ejca.2004.04.032)
  • 25. (a). E. Alessio, G. Mestroni, A. Bergamo, G. Sava. Curr. Top. Med. Chem. 4, 1525 (2004); (http://dx.doi.org/10.2174/1568026043387421)
  • 25. (b). E.Alessio, G. Mestroni, A. Bergamo, G. Sava. Metal Ions Biol. Sys. 42, 323 (2004).
  • 26. C. G. Hartinger, S. Zorbas-Selfried, M. A. Jakupee, B. Kynast, H. Zorbas, B. K. Keppler. J. Inorg. Biochem. 100, 891 (2006). (http://dx.doi.org/10.1016/j.jinorgbio.2006.02.013)
  • 27. Y. K. Yan, M. Melchart, A. Habtemariam, P. J. Sadler. Chem. Commun. 4764 (2005). (http://dx.doi.org/10.1039/b508531b)
  • 28. V. Brabec, O. Novakova. Drug Resist. Updates 9, 111 (2006). (http://dx.doi.org/10.1016/j.drup.2006.05.002)
  • 29. O. Novakova, J. Kasparkova, V. Bursova, C. Hofr, M. Vojtiskova, H. Chen, P. J. Sadler, V. Brabec. Chem. Biol. 12, 121 (2005). (http://dx.doi.org/10.1016/j.chembiol.2004.11.008)
  • 30. W. H. Ang, P. J. Dyson. Eur. J. Inorg. Chem. 4003 (2006). (http://dx.doi.org/10.1002/ejic.200600723)
  • 31. G. Jaouen (Ed.). Bioorganometallics: Biomolecules, Labelling, Medicine, Wiley-VCH, Weinheim (2005).
  • 32. A. Vessieres, S. Top, W. Beck, E. Hillard, G. Jaouen. Dalton Trans. 529 (2006). (http://dx.doi.org/10.1039/b509984f)
  • 33. C. Boit. Curr. Med. Chem. Anti-Infect. Agents 3, 135 (2004).
  • 34. M. M. Harding, G. Mokdsi. Curr. Med. Chem. 7, 1289 (2000).
  • 35. O. Oberschmidt, A. R. Hanauske, C. Pampillon, N. J. Sweeney, K. Strohfeldt, M. Tacke. Anticancer Drugs 18, 317 (2007). (http://dx.doi.org/10.1097/CAD.0b013e3280115f86)
  • 36. (a). O. R. Allen, L. Croll, A. L. Gott, R. J. Knox, P. C. McGowan. Organometallics 23, 288 (2004); (http://dx.doi.org/10.1021/om030403i)
  • 36. (b). G. D. Potter, M. C. Baird, M. Chan, S. P. Cole. Inorg. Chem. Commun. 9, 1114 (2006). (http://dx.doi.org/10.1016/j.inoche.2006.07.019)
  • 37. (a). A. V. Rudnev, L. S. Foteeva, C. Kowol, R. Berger, M. A. Jakupec, V. B. Arion, A. R. Timerbaev, B. K. Keppler. J. Inorg. Biochem. 100, 1819 (2006); (http://dx.doi.org/10.1016/j.jinorgbio.2006.07.003)
  • 37. (b). M. A. Jakupec, B. K. Keppler. Curr. Top. Med. Chem. 4, 1575 (2004). (http://dx.doi.org/10.2174/1568026043387449)
  • 38. R. Martinez, L. Chacon-Garcia. Curr. Med. Chem. 12, 127 (2005).
  • 39. P. G. Baraldi, A. Bovero, F. Fruttarolo, D. Preti, M. A. Tabrizi, M. G. Pavani, R. Romagnoli. Med. Res. Rev. 24, 475 (2004). (http://dx.doi.org/10.1002/med.20000)
  • 40. C. A. Frederick, L. D.Williams, G.Ughetto, G. A.van der Marel, J. H.van Boom, A.Rich, A.H.Wang. Biochemistry 29, 2538 (1990). (http://dx.doi.org/10.1021/bi00462a016)
  • 41. F. Pierard, A. Kirsch-De Mesmaeker. Inorg. Chem. Commun. 9, 111 (2006). (http://dx.doi.org/10.1016/j.inoche.2005.10.016)
  • 42. B. Onfelt, P. Lincoln, B. Norden. J. Am. Chem. Soc. 123, 3630 (2001). (http://dx.doi.org/10.1021/ja003624d)
  • 43. P. Lincoln, B. Norden. PCT/SE98/01655, (1998). The agent is not active in some other cell lines: B. Onfelt, L. Gostring, P. Lincoln, B. Norden, A. Onfelt. Mutagenesis 17, 317 (2002).
  • 44. A. C. G. Hotze, E. P. L. van der Geer, H. Kooijman, A. L. Spek, J. G. Haasnoot, J. Reedijk. Eur. J. Inorg. Chem. 2648 (2005). (http://dx.doi.org/10.1002/ejic.200500110)
  • 45. U. K. Mazumder, M. Gupta, S. S. Karki, S. Bhattacharya, S. Rathinasamy, S. Thangavel. Chem. Pharm. Bull. 52, 178 (2004). (http://dx.doi.org/10.1248/cpb.52.178)
  • 46. (a). M. J. Hannon, V. Moreno, M. J. Prieto, E. Moldrheim, E. Sletten, I. Meistermann, C. J. Isaac, K. J. Sanders, A. Rodger. Angew. Chem., Int. Ed. 40, 880 (2001);
  • 46. (b). I. Meistermann, V. Moreno, M. J. Prieto, E. Moldrheim, E. Sletten, S. Khalid, M. Rodger, J. Peberdy, C. J. Isaac, A. Rodger, M. J. Hannon. Proc. Natl. Acad. Sci. USA 99, 5069 (2002); (http://dx.doi.org/10.1073/pnas.062634499)
  • 46. (c). L. J. Childs, J. Malina, B. E. Rolfsnes, M. Pascu, M. J. Prieto, M. J. Broome, P. M. Rodger, E. Sletten, V. Moreno, A. Rodger, M. J. Hannon. Chem.Eur. J. 12, 4919 (2006); (http://dx.doi.org/10.1002/chem.200600060)
  • 46. (d). C. Uerpmann, J. Malina, M. Pascu, G. J. Clarkson, V. Moreno, A. Rodger, A. Grandas, M. J. Hannon. Chem.Eur. J. 11, 1750 (2005); (http://dx.doi.org/10.1002/chem.200401054)
  • 46. (e). S. Khalid, M. J. Hannon, A. Rodger, P. M. Rodger.Chem.Eur. J. 12, 3493 (2006). (http://dx.doi.org/10.1002/chem.200501168)
  • 47. A. Oleksi, A. G. Blanco, R. Boer, I. Uson, J. Aymami, A. Rodger, M. J. Hannon,M. Coll. Angew. Chem., Int. Ed. 45, 1227 (2006). (http://dx.doi.org/10.1002/anie.200503822)
  • 48. L. Cerasino, M. J. Hannon, E. Sletten. Inorg. Chem. 46, 6245 (2007). (http://dx.doi.org/10.1021/ic062415c)
  • 49. J. Malina, M. J. Hannon, V. Brabec. Chem.Eur. J. 14, 3871 (2007). (http://dx.doi.org/10.1002/chem.200700159)
  • 50. (a). G. I. Pascu, A. C. G. Hotze, C. Sanchez Cano, B. M. Kariuki, M. J. Hannon. Angew. Chem., Int. Ed. 46, 4374 (2007); (http://dx.doi.org/10.1002/anie.200700656)
  • 50. (b). M. J. Hannon, A. Rodger, N. H. Mann. PCT/GB2004/004227 (2004).
  • 51. A. C. G. Hotze, B. M. Kariuki, M. J. Hannon. Angew. Chem., Int. Ed. 45, 4839 (2006). (http://dx.doi.org/10.1002/anie.200601351)
  • 52. (a). A. C. G. Hotze, S. E. Caspers, D. de Vos, H. Kooijman, A. L. Spek, A. Flamigni, M. Bacac, G. Sava, J. G. Haasnoot, J. Reedijk. J. Biol. Inorg. Chem. 9, 354 (2004); (http://dx.doi.org/10.1007/s00775-004-0531-6)
  • 52. (b). A. H. Velders, K. van der Schilden, A. C. G. Hotze, J. Reedijk, H. Kooijman, A. L. Spek. Dalton Trans. 448 (2004). (http://dx.doi.org/10.1039/b313182c)
  • 53. S. Komeda, T. Moulaei, K. K. Woods, M. Chikuma, N. P. Farrell, L. D. Williams. J. Am. Chem. Soc. 128, 16092 (2006). (http://dx.doi.org/10.1021/ja062851y)
  • 54. (a). A. L. Harris, X. H. Yang, A. Hegmans, L. Povirk, J. J. Ryan, L. Kelland, N. P. Farrell. Inorg. Chem. 44, 9598 (2005); (http://dx.doi.org/10.1021/ic051390z)
  • 54. (b). A. L. Harris, J. J. Ryan, N. Farrell. Mol. Pharm. 69, 666 (2006).
  • 55. (a). See, for example, S. Top, E. B. Kaloun, A. Vessieres, G. Leclercq, I. Laios, M. Ourevitch, C.Deuschel, M. J. McGlinchey, G. Jaouen. ChemBioChem 4, 754 (2003);
  • 55. (b). M. J. Hannon, P. S. Green, D. M. Fisher, P. J. Derrick, J. L. Beck, S. J. Watt, M. M. Sheil, P. R. Barker, N. W. Alcock, R. J. Price, K. J. Sanders, R. Pither, J. Davis, A. Rodger. Chem.Eur. J. 12, 8000 (2006); (http://dx.doi.org/10.1002/chem.200501012)
  • 55. (c). K.R.Barnes, A. Kutikov, S. J. Lippard. Chem. Biol. 11, 557 (2004); (http://dx.doi.org/10.1016/j.chembiol.2004.03.024)
  • 55. (d). V. Perron, D. Rabouin, E. Asselin, S. Parent, R. C. Gaudreault, G. Berube. Bioorg. Chem. 33, 1 (2005); (http://dx.doi.org/10.1016/j.bioorg.2004.06.009)
  • 55. (e). M. Galanski, B. K. Keppler. Anticancer Agents Med. Chem. 7, 55 (2007);
  • 55. (f). K. H. Thompson, C. Orvig. Dalton Trans. 761 (2006). (http://dx.doi.org/10.1039/b513476e)
  • 56. See, for example, L. J. Childs, M. J. Hannon. Supramol. Chem. 16, 7 (2004).